Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of “Moderate Buy” from Analysts

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $7.33.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th.

Insider Activity at Amylyx Pharmaceuticals

In related news, Director Bernhardt G. Zeiher bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was purchased at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $37,000. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Joshua B. Cohen sold 11,851 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $3.47, for a total transaction of $41,122.97. Following the transaction, the chief executive officer now directly owns 3,201,247 shares in the company, valued at approximately $11,108,327.09. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,169 shares of company stock worth $97,274 in the last three months. 11.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMLX. Boxer Capital Management LLC acquired a new position in shares of Amylyx Pharmaceuticals during the 4th quarter valued at $6,615,000. Bank of America Corp DE boosted its stake in Amylyx Pharmaceuticals by 165.9% during the fourth quarter. Bank of America Corp DE now owns 2,426,263 shares of the company’s stock valued at $9,171,000 after buying an additional 1,513,748 shares in the last quarter. Walleye Capital LLC grew its holdings in Amylyx Pharmaceuticals by 986.5% during the third quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock worth $2,173,000 after acquiring an additional 608,874 shares during the period. Cubist Systematic Strategies LLC raised its position in Amylyx Pharmaceuticals by 862.5% in the fourth quarter. Cubist Systematic Strategies LLC now owns 472,397 shares of the company’s stock worth $1,786,000 after acquiring an additional 423,316 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in Amylyx Pharmaceuticals by 122.4% in the 4th quarter. Jane Street Group LLC now owns 765,475 shares of the company’s stock valued at $2,893,000 after acquiring an additional 421,302 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Down 5.4 %

AMLX opened at $3.66 on Monday. The company’s 50-day moving average price is $3.55 and its 200 day moving average price is $4.04. Amylyx Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $7.27. The firm has a market cap of $324.28 million, a price-to-earnings ratio of -0.96 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The company had revenue of ($0.67) million during the quarter. Research analysts anticipate that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.